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Abstract
Background: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is
a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene
mutation and accumulation of the p53 protein are closely related with serum anti-p53 antibody positivity. This
study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer
(mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.
Methods: Ninety patients treated with fluoropyrimidine, oxaliplatin plus bevacizumab as first-line chemotherapy
were enrolled, including 70 whose KRAS genotype was revealed at the beginning of treatment. Before
chemotherapy initiation, the serum p53 antibody level was quantified by enzyme-linked immunosorbent assay
using MESACUP® anti-p53 test kits. The cutoff value for positivity was 1.3 U/mL, as calculated previously. The KRAS
genotype of the tumor samples was analyzed using the Luminex® assay.
Results: Overall response rates of Response Evaluation Criteria in Solid Tumors criteria were 77.7 % (42/54) in
anti-p53–negative patients and 69.4 % (25/36) in anti-p53–positive patients. The odds ratio was 1.07. Median overall
survival was 36.1 months in the anti-p53–positive patients, and not available in the anti-p53–negative patients (hazard
ratio, 0.81; 95 % confidence interval, 0.37–1.77; P = 0.61). The corresponding values for median progression-free survival
were 13.3 months and 14.6 months (hazard ratio, 0.69; 95 % confidence interval, 0.41–1.17; P = 0.17), respectively.
Conclusions: Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with
fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.
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Background
In 1988, Vogelstein et al. proposed a multistage theory
of carcinogenesis known as the adenoma–carcinoma se-
quence, in which colorectal cancer (CRC) arises because
of mutations that activate multiple oncogenes and inacti-
vate tumor-suppressor genes. These mutations accumu-
late in the normal colonic epithelial cells and cause
adenomas. TP53 mutations were proposed as the driver
mutations in colorectal carcinogenesis [1].
Furthermore, the TP53 gene mutation is widely known
as an important determinant of impaired chemosensitivity
[2]. Approximately 40–50 % of CRC lesions are reported
to carry either a mutation in TP53 and/or loss of a hetero-
zygote at chromosome 17q, where TP53 is located [3].
Several in vitro studies have reported a relationship be-
tween TP53 mutation status and sensitivity to a number
of cytotoxic agents, including fluoropyrimidines [4]. Fur-
thermore, the presence of a TP53 mutation in tumors is
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associated with shorter patient survival compared with the
presence of wild-type TP53.
p53 is a tumor-suppressor protein encoded by the
TP53 gene in humans. Mutations commonly result in
expression of proteins with abnormal conformation,
which is readily detected as a p53 overexpression by
immunohistochemistry (IHC). Furthermore, p53 is cru-
cially involved in the control of the cell cycle and apop-
tosis and is also frequently altered in CRC. Some studies
have shown that TP53 gene mutation and accumulation
of the p53 protein are closely related with the presence
of serum anti-p53 antibodies [5]. Anti-p53 antibodies
are independent prognostic factors in esophageal and
ovarian cancer patients treated with chemotherapy [6].
Thus, the presence of serum p53 antibodies could theoret-
ically predict chemoresistance in metastatic CRC (mCRC)
treated with chemotherapy. However, no reports showed
about the relationship between anti-p53 antibody and
chemosensitivity in mCRC patients.
On the other hand, potential biomarkers include mu-
tations in KRAS and BRAF, which result in constitutive
signaling through the oncogenic Ras/Raf/MEK/ERK
pathway. Patients carrying tumors with KRAS muta-
tions are also reported to have a poorer prognosis. For
example, TP53 mutation in combination with KRAS
mutation at codon 13 are associated with a worse prog-
nosis in CRC [7]. However, no reports showed about
the relationship between anti-p53 antibody and KRAS
mutation.
Therefore, we investigated the relationship between
anti-p53 antibody and KRAS genotype and whether the
anti-p53 antibody status, IHC of p53 protein status and
KRAS genotype are correlated to chemosensitivity and
prognostic factors such as overall survival (OS) and
progression-free survival (PFS) in mCRC patients treated
with fluoropyrimidine, oxaliplatin, plus bevacizumab as
first-line chemotherapy.
Methods
This study has been performed in accordance with the
Declaration of Helsinki. The cancer Institute Hospital of
Japanese Foundation for Cancer Research, Institutional Re-
view Board approved this study (Registry number: 1278).
We obtained a comprehensive written informed consent
about the research before chemotherapy was started.
Study population
We enrolled 90 patients who confirmed mCRC and re-
ceived first-line chemotherapy (FOLFOX or XELOX
with Bev) at the Cancer Institute Hospital between Janu-
ary 2009 and November 2010, and measured anti-p53
antibody before receiving first-line chemotherapy.
Treatment and follow-up
The FOLFOX regimen was administered as follows: oxa-
liplatin on day 1 at a dose of 85 mg/m2 as a 2-h infusion
concurrent with levofolinic acid at 200 mg/m2/day,
followed by bolus 5-fluorouracil (5-FU) at 400 mg/m2
and a 22-h infusion of 5-FU at 2400 mg/m2 for 2 con-
secutive days. Bevacizumab was administered at a dose
of 5 mg/kg in a 30-min intravenous infusion on day 1 in
2-week cycles.
The XELOX regimen was administered as follows:
capecitabine (2000 mg/m2, biweekly) plus oxaliplatin
(130 mg/m2, day 1). Bevacizumab was administered at a
dose of 7.5 mg/kg in a 30-min intravenous infusion on
day 1 in 3-week cycles.
The treatment was repeated every 2 (or 3) weeks until
disease progression or unacceptable toxicity occurred, or
until a patient chose to discontinue treatment.
In our hospital, the patients underwent computed
tomography scans approximately every 3 months after
treatment completion and were regularly assessed for re-
sponse to chemotherapy and local or distant recurrence.
The evaluation was repeated every 3 (or 4) courses, or
more frequently in patients with clinically suspected pro-
gression. In this study, tumor response was reassessed via
computed tomography using the Response Evaluation
Criteria in Solid Tumors (RECIST), version 1.1.
Enzyme Immunoassay for p53antibody, IHC of p53
protein and KRAS genotyping
The serum anti-p53 antibody status was evaluated in
each patient before initiation of first-line chemotherapy.
The evaluation was performed by enzyme-linked im-
munosorbent assay (ELISA) using the anti-p53 ELISA
Kit (MESACUP, Nagoya, Japan). This kits have been de-
veloped with less variation in seropositivity (13–27 %)
with intra- and inter-assay coefficient of variation of
1.85–2.37 % and 0.3–3.32 % respectively [8]. For anti-
p53 autoantibodies, the cut off for positivity was set at
the average value among healthy subjects plus 3 standard
deviations or plus 1 standard deviation. The cut-off value
for positivity was calculated as 1.3 U/mL, as reported pre-
viously [2]. In addition, immunostaining was performed
with anti p53 protein antibody (D0-7,DAKO, Glostrup,
Denmark) on formalin-fixed paraffin-embedded fragments
obtained from those patients from whom adequate tissue
samples could be obtained by biopsy or surgical resection.
Nuclear staining of tumor cells were judged as positive for
p53 protein. The percentage of p53 positive cancer cells
was calculated compared with HE staining. The positive
rate of ≥ 70 % was determined as overexpression of p53
protein. The KRAS genotype of the tumor samples was
analyzed using the Luminex assay, as previously reported
[8]. The sensitivity of KRAS testing by Luminex has been
reported to be 10 % [9].
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Statistical analysis
Percentages were compared using the chi-square or
Fisher’s exact test when appropriate. Quantitative vari-
ables were compared using Student’s t test. Follow-up
was estimated using the Kaplan-Meier method. The cor-
relation between p53 antibody and the KRAS genotype,
IHC of p53 protein were estimated using Pearson’s
correlation coefficient. OS and PFS were estimated using
the Kaplan-Meier method and compared using the
log-rank test. PFS was defined as the interval begin-
ning with chemotherapy to relapse or death, whichever oc-
curred first. Variables associated with OS or PFS with
a P value <0.2 in a univariate analysis were included in a
multivariate ascending stepwise Cox regression analysis. In
the Cox model, continuous variables were dichotomized.
All statistical analyses were performed with EZR (Saitama
Medical Center, Jichi Medical University), which is a graph-
ical user interface for R (The R Foundation for Statistical
Computing). All reported P values were two-sided, and P
values <0.05 were considered significant.
Results
Patients characteristics (Table 1)
Between January 2009 and November 2010, 90 patients
were referred for first-line chemotherapy for mCRC.
Median age of the patients at the time of measuring anti-
p53 antibody was 61 years old (±9.1). This cohort was
composed of males (38.8 %) and females (61.2 %). Serum
anti-p53 antibodies were detected in 40.0 % patients (36/
90). IHC analyzed with monocloncal antibodies against
Table 1 Patients characteristics
ITT popuration (n = 90) KRAS wild type KRAS mutant
p53 antibody p53 antibody p53 antibody
Positive Negative Positive Negative Positive Negative
(n = 36) (n = 54) (n = 11) (n = 31) (n = 13) (n = 13)
Gender, n (%)
Male 25(69.4) 30(55.5) 9(81.8) 16(51.6) 9(69.2) 8(61.5)
Female 11(30.5) 24(44.4) 2(18.1) 15(48.3) 4(30.7) 5(38.4)
Age
Median (range) 58.4(39–74) 60.9(39–75) 57.3(41–73) 59.8(39–71) 59.3(39–74) 61.3 (41–75)
<65, n (%) 26(72.2) 31(59.2) 8(72.7) 19(61.2) 9(69.2) 6(46.1)
≧ 65, n (%) 10(27.7) 23(42.5) 3(27.2) 12(38.7) 4(30.7) 7(53.8)
ECOG PS at base line, n (%)
0 33(91.6) 51(94.4) 11(100) 30(96.7) 9(69.2) 12(92.3)
1 3(8.3) 3(5.5) 0(0) 1(3.1) 3(23.0) 1(7.7)
Liver metastasis, n (%) 12(33.3) 31(57.4) 7(63.6) 19(61.2) 3(23.0) 5(38.4)
Lung metastasis, n (%) 12(33.3) 22(40.7) 5(45.4) 9(29.0) 4(30.7) 8(61.5)
Lymph node metastasis, n (%) 21(66.6) 26(48.1) 8(72.7) 17(54.8) 8(61.5) 4(30.7)
ITT intention to treat, PS performance status
Table 2 Clinical response after 1st line chemotherapy
ITT popuration (n = 90) KRAS wild type KRAS mutant
p53 antibody p53 antibody p53 antibody
Positive Negative Positive Negative Positive Negative
n (%) n = 36 (n = 54) (n = 11) (n = 31) (n = 13) (n = 13)
Complete Response 5(13.8) 2(3.7) 1(9) 1(3.2) 3(23) 0(0)
Partial Response (PR) 21(58.3) 41(74.0) 9(81.8) 25(80.6) 7(53.8) 9(69.2)
Stable Disease 5(5.5) 10(18.5) 1(9) 3(9.7) 3(23) 4(30.7)
Progressive Disease 2(8.3) 1(1.8) 0(0) 1(3.2) 0(0) 0(0)
Not Evaluable 3(8.3) 0(0) 0(0) 1(3.2) 0(0) 0(0)
PR in 26(72.2) 43(79.6) 10(91) 26(83.8) 10(76.9) 9(69.2)
Odds ratio (95 % CI) 1.1 (0.55–2.21) 0.92 (0.3–2.8) 0.9 (0.23–3.43)
P value 0.87 1 1
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p53 of the patients was detected in 63 % (38/60). There
was no significant difference in background between the
anti-p53–positive and anti-p53–negative groups.
Correlation between anti-p53 antibody status and clinical
outcomes (n = 90)
Applying RECIST criteria (Table 2), the overall response
rate (ORR) was 77.7 % (42/54) in the anti-p53–negative
patients and 69.4 % (25/36) in the anti-p53–positive
patients. The odds ratio was 1.07. Median OS was
36.1 months in the anti-p53–positive patients and not
available (NA) in the anti-p53–negative patients [hazard
ratio (HR) 0.81, 95 % confidence interval (CI) 0.37–1.77,
P = 0.61]. The corresponding values for median PFS
were 13.3 months and 14.6 months (HR, 0.69; 95 % CI,
0.41–1.17; P = 0.17), respectively (Fig. 1).
Correlation between IHC of p53 protein status and clinical
outcomes (n = 60)
ORR according to RECIST criteria was 77.7 % (14/18)
and 76.1 % (32/42) in the p53 protein negative tumors
and the p53 protein positive tumors, respectively. The
odds ratio was 1.09.OS was 33.5 months in the p53 pro-
tein negative tumors, and NA in the p53 protein positive
tumors (HR 0.58, 95 % CI 0.21-1.6, P = 0.3). PFS was
13.36 months, and 13.3 months (Table 2), respectively
(HR 1.0, 95 % CI 0.51-1.9, P = 0.99) (Fig. 2). The esti-
mated correlation between anti-p53 antibody positivity
and the IHCof p53 protein positive tumors was 0.32
(95 % CI 0.07–0.53, P = 0.012).
Fig. 1 Overall survival and progression-free survival curves according to p53 antibody status for the entire population (n = 90)
Fig. 2 Overall survival and progression-free survival curves according to IHC of p53 protein status (n = 60)
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Correlation between anti-p53 antibody status and KRAS
genotype (n = 70) (Table 2)
In the KRAS wild-type (n = 42) patients, ORR according
to RECIST was 90.9 % and 83.8 % in the anti-p53–negative
patients and anti-p53–positive patients, respectively.
Median OS was 35.6 months in all patients, 35.6 months
in the anti-p53–negative patients, and NA in the anti-
p53–positive patients (HR 0.65, 95 % CI 0.18–2.33, P =
0.5). The corresponding values for median PFS were
14.6 months in total, 17.9 months, and 16.7 months, re-
spectively (HR 1.06, 95 % CI 0.48–2.31, P = 0.88) (Fig. 3).
In the KRAS mutant-type (n = 26) patients, ORR accord-
ing to RECIST was 69.2 % (9/13) and 76.9 % (10/13) in
the anti-p53–negative patients and anti-p53–positive
patients, respectively. Median OS was 33.8 months in all
patients, 13.8 months in the anti-p53–negative patients,
and 15.8 months in the anti-p53–positive patients (HR
0.52, 95 % CI 0.21–1.28, P = 0.15). The corresponding
values for median PFS were 14.6 months, 34.3 months,
and 26.6 months, respectively (HR 1.18, 95 % CI 0.33–4.1,
P = 0.79) (Fig. 4). The estimated correlation between anti-
p53 antibody positivity and the KRAS genotype was 0.037
(95 % CI 0.20–0.27, P = 0.746).
Univariate and murtivariate analysis
In univariate analysis, peritoneal metastasis and multiple
metastasis were also significant predictors of OS. On the
Fig. 3 Overall survival and progression-free survival curves according to p53 antibody status for the KRAS wild-type population (n = 44)
Fig. 4 Overall survival and progression-free survival curves according to p53 antibody status for the KRAS mutant-type population (n = 26)
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other hand, lung metastasis and lymph node metastasis
were also significant predictors of PFS. In the multivariate
analysis, peritoneal metastasis was significant predictors of
OS and lung metastasis and lymph node metastasis were
significant predictors of PFS. However both anti-p53 anti-
body and IHC of p53 protein negativity did not yield any
independent predictive factors (Table 3).
Discussion
To our knowledge, this retrospective study is the first to
evaluate the predictive significance of the presence of
anti-p53 antibodies and its correlation with the KRAS
genotype in CRC patients treated with first-line chemo-
therapy. No correlation was observed between anti-p53
antibody positivity and ORR. Furthermore, no correl-
ation was observed between anti-p53 antibody positivity
and the KRAS genotype.
The mechanism underlying anti-p53 auto-antibody
production has yet to be revealed but is thought to be as-
sociated with the presence of the TP53 mutation and p53
protein overexpression. Anti-p53 autoantibody frequency
was then correlated with reported TP53 mutation rates to
Table 3 Univariate and multivariate analysis
Univariate analysis
OS HR Lower 95 % CI Upper 95 % CI p.value
Gender (male or female) 0.76 0.34 1.67 0.5
Age (<65 or 2^ 65) 0.98 0.94 1.03 0.5
Performance status (0 or 1) 1.78 0.42 7.5 0.43
Resection of primary tumor (yes or no) 0.7 0.2 1.6 0.43
Ascitis (yes or no) 1.7 0.7 4.1 0.22
Liver metastasis (yes or no) 1.2 0.59 2.6 0.55
Lung metastasis (yes or no) 0.77 0.34 1.7 0.51
Lymph metastasis (yes or no) 1.9 0.86 4.2 0.1
Multiple metastasis (yes or no) 2.5 1.1 5.9 0.03
Peritoneal metastasis (yes or no) 2.5 1.2 5.2 0.01
Anti p53 antibody (positive or negative) 0.8 0.3 1.7 0.61
IHC of p53 protein (positive or negative) 0.58 0.21 1.6 0.3
KRAS (wild or mutant) 1.29 0.54 2.75 0.63
PFS
Gender (male or female) 1.6 0.9 3.03 0.1
Age (<65 or^65) 0.99 0.96 1.02 0.53
Performance status (0 or 1) 1.8 0.23 2.47 0.64
Resection of primary tumor (yes or no) 1.5 0.72 3.1 0.99
Ascitis (yes or no) 0.6 0.28 1.43 0.29
Liver metastasis (yes or no) 0.54 0.28 1 0.07
Lung metastasis (yes or no) 2.8 1.59 5.2 4E-04
Lymph metastasis (yes or no) 0.47 0.26 0.85 0.01
Multiple metastasis (yes or no) 0.9 0.51 1.6 0.72
Peritoneal metastasis (yes or no) 0.73 0.37 1.45 0.27
Anti p53 antibody (positive or negative) 0.9 0.49 1.6 0.73
IHC of p53 protein (positive or negative) 1 0.51 1.9 0.99
KRAS (wild or mutant) 0.98 0.49 1.9 0.94
Multivariate analysis
OS HR Lower 95 % CI Upper 95 % CI p.value
Peritoneal metastasis (yes or no) 2.3 1.1 5.1 0.02
PFS
Lung metastasis (yes or no) 2.46 1.34 4.51 0.003
Lymph metastasis (yes or no) 0.5 0.28 0.97 0.04
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determine the association between anti-p53 antibody posi-
tivity and the TP53 mutation status (CRC: TP53 mutation
43.3 %, anti p53 antibody positivity 21.4 %). Moderate cor-
relation (r2 = 0.45, correlation 0.59) was found to exist be-
tween anti-p53 antibody positivity and the TP53 mutation
[10]. Mutational loss of the tumor-suppressor functions of
TP53 has been associated with decreased sensitivity to
agents inhibiting DNA synthesis, such as 5-FU [11]. These
genetic alterations play crucial roles in colorectal carcino-
genesis, including DNA damage signaling and the response
to platinum-based chemotherapeutic agents.
As mentioned above, preclinical research has indicated
that disruptions in the Ras/Raf/MEK/ERK pathway or
inactivation of the TP53 tumor-suppressor gene may
have clinical relevance to the efficacy of anti-VEGF
agents, such as bevacizumab.
However, in this retrospective study, we did not assess
mCRC patients who were more likely to respond to bev-
acizumab therapy.
There are some reasons to explain the results of this
study. First, An Anti-p53 antibody is not normally pro-
duced wild type p53 protein induces tolerance of the
host. However TP53 mutation alone is insufficient to
trigger anti-p53 antibody production. Only 20–50 % of
patients which detectable TP53 mutations produce de-
tectable anti-p53 antibodies [12]. This is attributed to
Table 4 p53 status and prognosis of colorectal cancer: past literature date







Overall survial Survival Response
LAN YT [10] 258 ACC surgery - + - 37.6(IHC) univariate NA NA
Triantafyllou K [11] 55 Adenoma Polypectomy - + - 41.8DtHCD NA murtivariate NA
Wang Q [12] 40 ACC surgery - + - 65 OHCD univariate NA NA
Hu J [13] 120 ACC biopsy and surgery - + - 57 OHCD univariate NA NA
Grewal H [14] 66 ACC surgery - + - 51.5(IHC) NS NA NA
Bouzourenne H [15] 122 ACC surgery - + + 47(IHC) univariate NA NA
32(S) murtivariate
Samowitz WS [16] 1464 ACC biopsy and surgery - - + 45.4DSD univariate NA NA
Chang SC [17] 167 ACC surgery + - + 28.1(Ab) univariate NA NA
56.3(S) murtivariate
Angelopoulou K [18] 229 ACC biopsy and surgery + - - 23(Ab) NS NS NA
Kressner U [19] 184 ACC surgery + - - 32(Ab) univariate NA NA
Suppiah A [20] 28 ACC surgery + - - 21,7(Ab) NS NS NA
Kreessner U [21] 294 ACC biopsy + - - 55DAbD NS NA NA
Ab antibody; IHC immunohistochemistry; S sequencing; ACC advanced colorectal cancer; NA not available; NS not significant
Table 5 p53 status and prognosis of colorectal cancer: comparison between literature deta and the present report
Reference n Histology treatment Methods for
determing
p53 Ab







Popat S [22] 967 CRC Adjuvant - + - 60 (IHC) NS NA NA
Zaana A [23] 233 CRC Adjuvant - + - 53 (IHC) NA NS NA
Ahn MJ [24] 45 mCRC chemotherapy - + - 80 (IHC) NA NA NS
Berglund A [25] 122 mCRC chemotherapy - + - 60 (IHC) NS NA NS
Ince WL [26] 295 CRC chemotherapy - + + 68 (IHC), 72(S) NS, NS NA NA
Mollevi DG [27] 91 mCRC chemotherapy - - + 50.5 (S) multivariate NA NA
Rosty C [28] 56 mCRC chemotherapy - - + 62.5 (S) univariate NA NS
Westra JL [29] 220 CRC Adjuvant - - + 53(S) NA murtivariate NA
Oden-Gangloff [30] 64 mCRC chemotherapy - - + 64(S) NA murtivariate NA
Present study 90 mCRC chemotharapy + + - 40(Ab), 63(IHC) NS,NS NS,NS NS,NS
Ab antibody; IHC immunohistochemistry; S sequencing; (m)CRC (metastatic) colorectal cancer; NA not available; NS not significant
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the type of mutation, mis-sense mutations is associated
with higher antibody production compared with other
mutation [13]. Second anti-p53 antibodies most fre-
quency recognize terminal epitopes but not the central
domain with majority of the mutation [8]. Third, the
differences in individual’s immune systems might relate,
the humoral response is independent on the individual’s
MHC presentations [8].
The methods used to determine the mutational status
of TP53 or KRAS merit discussion. Indeed, the question
is whether anti-p53 antibodies are a reliable parameter
for the TP 53 mutation status. These antibodies have
high specificity but lack sensitivity [4]. They have the
same drawbacks as immunohistochemistry because they
are absent in patients in whom TP53 mutations negate
p53 protein synthesis and accumulation.
In this study we also investigate whether IHC of p53
protein was the predictive factor of chemosensitivity or
not, however there was no relationship between IHC of
p53 protein and clinical outcomes.
Other techniques, such as sequencing and functional
assays, have been developed to determine the mutation
status of TP53 as it applies to CRC. In previous studies,
perioperative variations in serum anti-p53 antibody levels
have been shown to predict OS (Table 4) [12, 14–24].
However, only the sequencing data were correlated with
the level of chemoresistance (Table 5) [4, 11, 25–31].
Anti-p53 antibody has low sensitivity in CRC but is nearly
100 % specific for malignancy. Thus, we believe anti-p53
antibody measurement is suitable and cost-effective for
screening a high-risk population and for postoperative
cancer surveillance as a guide for earlier detection of
recurrence [29].
This study had some limitations. Because of its retro-
spective and single-center nature, an unknown bias may
exist in the findings. Furthermore, we didn’t measure
TP53 mutation using sequencing method which is one
of the main methods of detect TP53 mutation. When we
assess the relationship between TP53 gene mutation and
chemoresistance in mCRC patients, we should use other
methodologies such as sequencing and functional assays,
apart from the anti-p53 antibody status.
Conclusion
Serum anti-p53 antibody positivity did not predict che-
moresistance in mCRC treated with fluoropyrimidine,
oxaliplatin, plus bevacizumab at first-line chemotherapy.
We believe that if we want to know the relationship be-
tween the anti-p53 antibody status and chemosensitivity,
we should use other methodologies like sequencing, and
functional assays, apart from the anti-p53 antibody status.
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